Selecta Biosciences (SELB) Commences Dosing of SEL-212 Phase 2 as Gout Treatment
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Selecta Biosciences, Inc. (Nasdaq: SELB) announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product candidate for the treatment of chronic gout in patients refractory to conventional therapy. This trial will assess the safety, tolerability and clinical activity of SEL-212, a combination product candidate consisting of pegsiticase (pegylated uricase) and SVP-Rapamycin. SEL-212 is designed to be the first non-immunogenic enzyme therapy for gout. Initial results from this trial are expected in the first half of 2017.
“SEL-212 has the potential to address the large unmet need of severe gout patients, who are currently lacking effective treatment options. By lowering serum uric acid levels and total body uric acid burden with multiple doses of SEL-212 covering up to 6 months of treatment, SEL-212 is designed to eliminate inflammatory deposits that cause debilitating pain and often serious damage to joints and organs,” said Earl Sands, M.D., Selecta’s Chief Medical Officer. “The initiation of this trial marks an important advancement for our Synthetic Vaccine Particles (SVP) immunotherapeutic platform, which has the potential to enable and enhance a large number of biologic therapies including enzyme therapies, gene therapies and biologic cancer treatments by antigen-specific mitigation of undesired immune responses such as neutralizing antibodies.”
This Phase 2 clinical trial of SEL-212 is being conducted at 15 centers in the United States and is expected to enroll more than 36 symptomatic gout patients with elevated uric acid levels. The primary and secondary endpoints of the trial include safety and tolerability of multiple doses of SEL-212, reduction of serum uric acid levels and mitigation of anti-drug antibodies (ADAs). Exploratory endpoints include measurement of uric acid deposits by Dual Energy Computed Tomography (DECT) imaging. Multiple dose treatment with SEL-212 has the potential to significantly lower total uric acid crystal burden in joints and tissues, which cannot be effectively or rapidly achieved by oral gout therapy. The removal of the uric acid crystal deposits is expected to reduce overall inflammation and the frequency of debilitating gout flares.
SEL-212 exemplifies Selecta’s strategy to combine its SVP-Rapamycin platform with targeted biologics that require repeat administration to prevent the formation of ADAs. Undesired immune responses such as ADAs are a common complication with biologics including enzyme therapies, gene therapies, and cancer treatments. Application of the SVP platform may yield a pipeline of products with improved therapeutic benefit resulting from the reduction of unwanted immune responses. Selecta aims to advance a series of programs, including novel gene therapy products.
Phase 1 Data to be Presented December 7-8, 2016
In the Phase 1 clinical program of SEL-212, active and generally well-tolerated doses of pegsiticase and SVP-Rapamycin were identified in two single ascending dose trials with more than 75 patients. SVP-Rapamycin prevented the formation of ADAs and enabled pegsiticase to maintain sustained control of serum uric acid levels for at least 30 days after a single dose.
On Wednesday, December 7, 2016 at the 11th Annual Immunization and Vaccine Summit (IMVACS) in Boston, MA, Selecta will present results from this Phase 1 program. These results will also be discussed on a live conference call and webcast on Thursday, December 8, 2016 at 8:30 a.m. ET.
About Chronic Refractory and Tophaceous Gout
More than 8 million patients in the United States suffer from gouti, which is caused by elevated levels of uric acid that result in harmful crystalline uric acid deposits in joints and surrounding tissues that cause painful inflammation and can lead to joint damage. Severe gout is often poorly controlled with conventional oral medications, resulting in painful and debilitating disease, flares, and nodular masses of uric acid crystals termed tophi. Approximately 50,000 patients in the United States have been diagnosed with chronic refractory goutii, an orphan indication defined as uric acid levels that cannot be controlled by high doses of available oral therapies. It is also estimated that more than 200,000 patients in the United States suffer from chronic gout with tophiiii, or tophaceous gout, which typically affects joints and surrounding soft tissues at the fingers, toes or elbows. Tophi are a difficult to treat source of chronic pain, inflammation, and can cause joint damage. Tophi typically take many years to resolve, or may fail to resolve, with conventional oral uric acid lowering therapy for goutiv. Treatment options to improve chronic refractory and tophaceous gout are very limited. Currently available uricase therapy fails to resolve gout and tophi in a majority of patients, largely because of unwanted immune reactions leading to the formation of antibodies that compromise efficacy and can cause serious adverse eventsv.
SEL-212 is Selecta’s proprietary product candidate for the treatment of chronic refractory gout. SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, a pegylated uricase. Selecta believes that SEL-212 has the potential to offer an effective treatment for patients with chronic refractory and tophaceous gout, while also demonstrating the clinical effectiveness of the company’s SVP technology.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Internet Bancorp (INBK) Names Nicole Lorch as COO
- Silgan (SLGN) to Acquire WestRock's (WRK) Specialty Closures and Dispensing Systems Business for $1.03B
- Theravance Biopharma (TBPH) Reports Interim Data from TOUR Study in Oral Presentation at SCCM
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Related EntitiesIPO, AdCom
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!